2-(3,3-dimethylbutyl)pyridine | 60263-44-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(3,3-dimethylbutyl)pyridine
• 英文别名: 2-(3,3-dimethyl-butyl)-pyridine；2-(3',3'-Dimethylbutyl)-pyridin
• CAS: 60263-44-7
• 化学式: C₁₁H₁₇N
• 分子量: 163.263
• InChiKey: UDKWYRGEQAXLSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3,3-二甲基-1-丁烯 在 [(cod)₂RhCl]₂ 氢氟酸 、 tricyclohexylphosphonium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 47.0h， 生成 2-(3,3-dimethylbutyl)pyridine
  参考文献：
  名称：

  Rh(I)-Catalyzed Alkylation of Quinolines and Pyridines via C−H Bond Activation

  摘要：

  The scope of heterocycle ortho-alkylation has been dramatically expanded to include pharmaceutically important pyridines and quinolines, which contain only a single nitrogen. The reactions, which are conducted at a high concentration (0.8 M), can be performed with catalyst loadings as low as 1% Rh. Substitution ortho to the heterocycle ring nitrogen is required for efficient alkylation and is consistent with the intermediacy of a Rh-carbene intermediate similar to those proposed in our earlier work.

  DOI：

  10.1021/ja070388z

文献信息

• C2-selective alkylation of pyridines by rhodium–aluminum complexes
  作者：Naofumi Hara、Koki Aso、Qiao-Zhi Li、Shigeyoshi Sakaki、Yoshiaki Nakao

  DOI：10.1016/j.tet.2021.132339

  日期：2021.8

  mono-selective alkylation of various pyridines and azines with unactivated alkenes and vinylarenes using a heterobimetallic Rh–Al catalyst is reported. The use of aliphatic alkenes exclusively affords the linear alkylation products, while vinylarenes mainly afford branched alkylation products. The details of the reaction mechanism are revealed by DFT calculations: the reductive elimination of the products

  报道了使用杂双金属 Rh-Al 催化剂对各种吡啶和吖嗪与未活化的烯烃和乙烯基芳烃进行 C2 和单选择性烷基化反应。脂肪族烯烃的使用专门提供线性烷基化产物，而乙烯基芳烃主要提供支化烷基化产物。通过DFT计算揭示了反应机理的细节：产物的还原消除是定速的，这与实验结果一致。基于变形/相互作用分析阐明了线性/分支选择性的起源。
• Fe-Catalyzed Reductive Couplings of Terminal (Hetero)Aryl Alkenes and Alkyl Halides under Aqueous Micellar Conditions
  作者：Haobo Pang、Ye Wang、Fabrice Gallou、Bruce H. Lipshutz

  DOI：10.1021/jacs.9b04510

  日期：2019.10.30

  aromatic or heteroaromatic and an alkyl bromide or iodide leads, in the presence of Zn and a catalytic amount of an Fe(II) salt, to a net reductive coupling. The new C-C bond is regiospecifically formed at rt at the -site of the al-kene. The coupling only occurs in an aqueous micellar medium, where an atypical carbanionic, as opposed to radical, process is likely, supported by several control experiments

  在Zn和催化量的Fe(II)盐的存在下，乙烯基取代的芳族或杂芳族和烷基溴或碘的组合导致净还原偶联。新的 CC 键在 rt 在烯烃的  位点区域特异性地形成。偶联仅发生在水性胶束介质中，其中可能是非典型的碳负离子过程，而不是自由基过程，这得到了几个控制实验的支持。提出了一种基于这些数据的机制。
• SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY
  申请人：Northwestern University

  公开号：US20170001976A1

  公开（公告）日：2017-01-05

  Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.

  公开了具有取代喹唑啉核心结构的新小分子，以及它们用于调节葡萄糖苷脂酶活性的用途。还公开了包含这些小分子或与小分子结合的激活葡萄糖苷脂酶的药物组合物，这些组合物可以用于治疗与葡萄糖苷脂酶活性相关的疾病或失调，包括神经系统疾病和失调，如戈谢病和帕金森病。
• COMBINATION OF KINASE INHIBITORS AND USES THEREOF
  申请人：INTELLIKINE, LLC

  公开号：US20150030588A1

  公开（公告）日：2015-01-29

  The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.

  本发明提供了一种治疗与PI3-激酶a和/或受体酪氨酸激酶（RTK）有关的疾病状况的方法。另一方面，该发明提供了一种治疗与PI3-激酶α和/或受体酪氨酸激酶（RTK）有关的疾病状况的方法。另一方面，提出了一种抑制细胞中Akt（S473）磷酸化的方法。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Ren Pingda

  公开号：US20120122838A1

  公开（公告）日：2012-05-17

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及与激酶活性相关的疾病和病况的化合物、药物组合物和治疗方法在此进行描述。